GlassScriptPhysician profile
Ellen L Conn
NPI 1881217719
$1,603.79
in general payments reported to CMS, 2019-2025
20 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $167 · 2023: $580 · 2024: $474 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $409.77 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $244.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $239.67 | 2022-2025 | |
| Amgen INC. | $131.25 | 2022-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $126.11 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.12 | 2022-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $51.97 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $37.94 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $37.73 | 2025 | Veozah |
| Organon LLC | $36.41 | 2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $35.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.74 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $24.66 | 2023 | Monoferric |
| Abiomed | $21.88 | 2024 | Impella |
| Dexcom, INC. | $21.24 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.79 | 2023 | Rexulti |
| Organogenesis INC. | $17.69 | 2025 | Via Matrix |
| Biohaven Pharmaceutical Holding Company LTD. | $15.02 | 2022 | |
| Ethicon US, LLC | $14.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.